• Stacy Lawlor

Global Organ On Chip Market Size to grow USD 1.6 Bn in 2028, CAGR of 31.5%

The Global Organ On Chip Market Size was valued at USD 103.4 Mn in 2021. The market is projected to grow USD 1.6 Bn in 2028, at a CAGR of 31.5%.

Global Organ On Chip Market Size to grow USD 1.6 Bn in 2028, CAGR of 31.5%

Request Free Sample To Learn More About This Report


An artificial organ that mimics human organs is known as an organ-on-chip. It's a three-dimensional (3D) microfluidic cell culture system that stimulates organ functions, processes, and physiological responses. Researchers have developed a new model of in vitro multicellular human organisms using a mix of labs-on-chips (LOCs) and cell biology to explore human physiology in an organ-specific environment. In organs such as the lung, gut, brain, liver, and heart, this chip creates a narrow channel for blood and air flow. These devices are built on a microchip with constantly perfused chambers populated by living cells that are configured to stimulate tissue and organ physiology. Organ-on-chip is a silicone-based technology that is used to nourish interior organs. Organ on chip has caught the interest of the medical and pharmaceutical worlds for the development of targeted medicines due to its benefits over cell culture, animal models, and human clinical trials. Organ-on-a-chip technology is presently being researched all around the world as a way to construct disease models and precisely forecast pharmaceutical efficacy and toxicity. This capability is expected to propel the market for organs on a chip to new heights.

Global Organ On Chip Market Size to grow USD 1.6 Bn in 2028, CAGR of 31.5%

Request Free Sample To Learn More About This Report


The growing prevalence of cardiovascular diseases (CVD) is likely to propel the organ-on-a-chip business to new heights. Organ-on-a-chip technologies were created to simulate the dynamic circumstances of the circulatory system, particularly the heart and the general vasculature. The structural organisation, shear stress, transmural strain, mechanical stretching, and electrical stimulation are all replicated in these systems. Heart-and-vasculature-on-a-chip platforms have previously been successfully developed to study a range of physiological phenomena, model illnesses, and test pharmacological effects.


The product segment is expected to dominate the market share of global organ on chip market owing to increased number of key players and growing number of partnerships and collaboration between pharmaceutical companies and organs-on-chips manufacturers as a result of technology breakthroughs and new product releases. The lung segment is expected to dominate the market share of global organ on chip market owing to lower lung transplants have led to the development of lab-engineered chips that replicate their functions and are used to screen drugs for respiratory illnesses. Lung-on-chip also offers a unique in vitro approach to drug screening by imitating the intricate mechanical and biochemical behaviours of a human lung, thanks to the combination of micro manufacturing techniques and contemporary tissue engineering. The drug discovery is expected to dominate the market share of global organ on chip market. The significant increase in demand for early detection of drug toxicity is also playing crucial role in the demand of drug discovery. The pharmaceutical segment is expected to dominate the market share of global organ on chip market owing to increasing applications of drug discovery including target validation, biomarker identification & validation, compound optimization, and preclinical safety assessment.


North America region is expected to dominate the market share of global organ on chip market owing to the The presence of key pharmaceutical companies, as well as the availability of new and advanced organs-on-chips models on the market, favourable government initiatives in terms of funding and programmes for basic drug development and research, and the availability of new and advanced organs-on-chips models on the market. Increased incidence of targeted diseases such as UI, bladder blockage, urine retention, Benign Prostate Hyperplasia (BPH), and bladder cancer is driving the regional market. As a result, the market in North America is being driven by an increase in the number of BPH-related surgical procedures and an increase in the number of occurrences of bladder cancer.

Global Organ On Chip Market Size to grow USD 1.6 Bn in 2028, CAGR of 31.5%

Request Free Sample To Learn More About This Report


However, Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period. The regional market is being driven by the countries like China, India, and Japan offer attractive opportunities. Furthermore, as the population's disposable income rises, the region's adoption of Organ-on-a-Chip technology is likely to rise. The expansion of the Organ-on-a-Chip market in the Asia-Pacific region is predicted to be aided by government support for regenerative medicines in research institutions, as well as an increase in the number of cell-based clinical trials and investment in R&D activities.


KEY INDUSTRY DEVELOPMENTS:


April 2022- NETRI launches its new organs-on-chip container, called NeoBento which offers an optimized user experience, in terms of handling and possibilities, chip assortment, compatibility, readouts amongst others.


February 2022- Researchers from MIMETAS and Astellas introduce OrganoPlate® 3-lane 40, a combination human renal proximal tubule/blood vessel-on-a-chip model to study acute kidney damage (AKI) caused by renal ischemia/reperfusion injury (rIRI). Kidney360 has recently published this story.


December 2021- Emulate, Inc. has announced that its Brain-Chip will be sent to the International Space Station U.S. National Laboratory (ISS National Lab) to study the effects of microgravity on human brain physiology (ISS-NL).


November 2021- TARA Biosystems collaborated with Scipher Medicine to address a critical unmet need for effective therapeutics in cardiac laminopathies.


August 2021- InSphero AG announced that the company is making their proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues.


March 2021- AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development.


Read More Details On This Report:

https://www.extrapolate.com/Healthcare-Medical-Devices-Biotechnology/organ-on-chip-market/25694

31 views